Le Lézard
Classified in: Health, Business
Subject: DIV

Hillrom Declares Fiscal 2021 Fourth Quarter Dividend


CHICAGO, July 8, 2021 /PRNewswire/ -- Hillrom (NYSE: HRC) announced today that its board of directors declared a fiscal 2021 fourth quarter dividend of $0.24 per share payable on September 30, 2021, to shareholders of record as of the close of business on September 17, 2021. The indicated annual dividend rate is $0.96 per share.

About Hillrom

Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Caretm. Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through connected smart beds, patient lifts, patient assessment and monitoring technologies, caregiver collaboration tools, respiratory health devices, advanced operating room equipment and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.

CONTACT INFORMATION

Investor Relations

Contact:     Mary Kay Ladone, Senior Vice President,

Contact:    Lorna Williams, Executive Director,

                    Corporate Development, Strategy and Investor Relations

                   Investor Relations and Strategy

Phone:        312-819-9387

Phone:       312-233-7799

Email:          [email protected]

Email:         [email protected]

 

Media
Contact: Howard Karesh, Vice President, Corporate Communications
Phone: 312-819-7268
Email: [email protected]

SOURCE Hillrom


These press releases may also interest you

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...

16 mai 2024
We are advised by Hidden River Eating Disorder Residential Treatment that journalists and other readers should disregard the news release, Hidden River Announces Insurance Contract with Blue Cross Blue Shield, issued 16-May-2024 over PR Newswire....

16 mai 2024
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43...



News published on and distributed by: